A case study highlights endomyocardial calcification associated with pulmonary and systemic hypertension in a neonate diagnosed with multisystem inflammatory syndrome of newborn (MIS-N). This research contributes to understanding the cardiovascular implications of MIS-N in infants.

Nearly 100 biotech companies went public in 2021, driven by pandemic investments, but many struggle to deliver results. Invivyd raised $336 million in a Series C round for its COVID-19 candidate ADG20, while Verve focuses on gene editing for cardiovascular diseases.

The CDC reports on the effectiveness of COVID-19 vaccines in children aged 9 months to 17 years, providing critical data for public health policy. This analysis covers the period from August 29, 2024, to September 2, 2025.

The CDC has launched a Nursing Home Data Dashboard featuring a COVID-19 module that tracks the impact on residents and staff in long-term care facilities. This initiative aims to enhance transparency and inform policy decisions regarding nursing home safety.

The FDA has issued Emergency Use Authorizations (EUA) for certain medical devices related to COVID-19, as mandated by the Federal Food, Drug, and Cosmetic Act. This announcement includes the requirement for the FDA to publish notices of each authorization in the Federal Register.

FDA revokes Emergency Use Authorizations for the Lucira by Pfizer COVID-19 & Flu Test and the Lucira by Pfizer COVID-19 & Flu Home Test at the request of Pfizer Inc. The decision reflects ongoing evaluations of diagnostic device efficacy and safety.

The HHS has rescinded the requirement for Head Start programs to implement a COVID-19 mitigation policy, as outlined in the January 2023 final rule. This change may impact operational protocols in early childhood education settings.